Pharma major Lupin announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Oseltamivir Phosphate Capsules, USP , 30 mg (base), 45 mg (base), and 75 mg (base) are  the generic equivalent of Hoffman-La Roche, Inc.'s  Tamiflu Capsules, 30 mg, 45 mg, and 75 mg. Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir Phosphate Capsules, USP had annual sales of approximately USD 518 million in the US (IQVIA MAT December 2017).

Shares of the company gained Rs 18.8, or 2.29%, to trade at Rs 839.70. The total volume of shares traded was 110,577 at the BSE (3.11 p.m., Monday).